Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.630
+0.220 (4.99%)
Nov 28, 2025, 1:00 PM EST - Market closed
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $5.18M in the quarter ending September 30, 2025, a decrease of -80.16%. This brings the company's revenue in the last twelve months to $43.69M, down -32.98% year-over-year. In the year 2024, Recursion Pharmaceuticals had annual revenue of $58.84M with 32.00% growth.
Revenue (ttm)
$43.69M
Revenue Growth
-32.98%
P/S Ratio
42.51
Revenue / Employee
$54,611
Employees
800
Market Cap
2.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.84M | 14.26M | 32.00% |
| Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
| Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
| Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
| Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RXRX News
- 6 days ago - Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Motley Fool
- 9 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Is Recursion Pharmaceuticals a Meme Stock? - The Motley Fool
- 12 days ago - Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? - Seeking Alpha
- 24 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 25 days ago - Recursion Announces CEO Transition Plan to Drive Next Phase of Growth - GlobeNewsWire
- 26 days ago - 3 Things Investors Need to Know About Recursion Pharmaceuticals - The Motley Fool